Becton Dickinson (NYSE: BDX) reported Q2 EPS of $2.55, $0.19 better than the analyst estimate of $2.36. Revenue for the quarter came in at $4.25 billion versus the consensus estimate of $4.16 billion.

"As the world responds to the COVID-19 pandemic, BD is focused on protecting the health and safety of our employees while addressing the critical health needs of our customers and their patients," said Tom Polen, CEO and president. "We are extremely proud of our team for their impact supporting healthcare providers on the front lines, launching several new diagnostic offerings to identify COVID-19 and ramping up production of essential medical devices. While our second quarter results were slightly ahead of our prior expectations, we are seeing the negative impact of coronavirus on certain parts of our business. We are confident that our diversified portfolio and the proactive actions we are taking will help us navigate these current challenges while positioning BD well as we continue to advance our long-term growth strategy."

Fiscal 2020 Outlook for Full Year

Due to ongoing uncertainty regarding the scope and duration of the COVID-19 global pandemic, as well as the timing and pace of recovery, the company is currently unable to estimate the impact to its financial results and operations over the balance of fiscal year 2020. As this impact could be material, the company is withdrawing its previously issued fiscal year 2020 revenue and earnings per share guidance.

For earnings history and earnings-related data on Becton Dickinson (BDX) click here.